Gregory Alan Otterson

Gregory Alan Otterson's AcademicInfluence.com Rankings

Medical

#3244

World Rank

#3703

Historical Rank

Oncology

#226

World Rank

#234

Historical Rank

medical Degrees

Gregory Alan Otterson

Philosophy

#9296

World Rank

#12834

Historical Rank

Logic

#6280

World Rank

#7786

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Gregory Alan Otterson's Degrees

Doctorate Medicine Johns Hopkins University
PhD Biomedical Sciences Johns Hopkins University

Why Is Gregory Alan Otterson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gregory Alan Otterson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) (2193)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. (2015) (1280)
Non-small cell lung cancer clinical practice guidelines in oncology. (2006) (1010)
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology (2017) (805)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients (2016) (509)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. (2019) (490)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. (2021) (423)
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (411)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. (2018) (411)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. (2016) (382)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial (2011) (380)
Non-Small Cell Lung Cancer, Version 6.2015. (2015) (373)
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. (1998) (366)
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers (2019) (364)
Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. (1994) (355)
Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. (1996) (350)
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines (2013) (313)
Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1 (2006) (287)
Methylation of Adjacent CpG Sites Affects Sp1/Sp3 Binding and Activity in the p21Cip1 Promoter (2003) (282)
Non-small cell lung cancer. (2012) (277)
Non-small cell lung cancer. Clinical practice guidelines in oncology. (2004) (269)
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). (2014) (266)
MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. (2008) (265)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (2019) (241)
Non-small cell lung cancer, version 2.2013. (2013) (234)
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. (2003) (232)
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. (2001) (228)
CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. (1995) (227)
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. (2014) (209)
Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration (2019) (206)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. (2019) (194)
Molecular pathways and therapeutic targets in lung cancer (2014) (186)
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. (2009) (178)
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. (2003) (166)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. (2020) (158)
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. (2006) (155)
Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. (2006) (155)
Non-small cell lung cancer, version 1.2015. (2014) (154)
Lung cancer screening: Clinical practice guidelines in oncology (2012) (154)
5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation* (2004) (154)
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. (2002) (149)
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (147)
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) (2017) (134)
Lung cancer exosomes as drivers of epithelial mesenchymal transition (2016) (129)
Romidepsin: a novel histone deacetylase inhibitor for cancer (2011) (128)
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. (1994) (127)
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). (2015) (126)
Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. (2006) (124)
Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. (1995) (120)
Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells (2001) (116)
Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs (2007) (116)
Pulmonary neuroendocrine/carcinoid tumors (2009) (116)
A Novel Classification of Lung Cancer into Molecular Subtypes (2012) (114)
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. (2015) (106)
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients (2016) (106)
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. (2004) (106)
Non-small cell lung cancer. (2010) (103)
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis (2019) (101)
Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. (1997) (101)
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study (2021) (91)
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. (2009) (90)
Global methylation profiling of lung cancer identifies novel methylated genes. (2001) (88)
Protein expression and functional analysis of the FHIT gene in human tumor cells. (1998) (88)
Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer (2010) (87)
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. (2019) (87)
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding (1997) (86)
The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro (1995) (85)
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). (2001) (81)
Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer (2012) (81)
Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort (2013) (81)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. (2021) (79)
HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells (2008) (77)
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. (2016) (76)
Unraveling the epigenetic code of cancer for therapy. (2007) (75)
MicroRNAs in the Pathogenesis of Lung Cancer (2009) (72)
Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers (2019) (69)
A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer (2004) (69)
Strong Inverse Correlation Between MicroRNA-125b and Human Papillomavirus DNA in Productive Infection (2010) (66)
CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung. (2015) (66)
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. (2012) (65)
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) (2010) (65)
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). (2012) (63)
Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. (2018) (62)
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer (2018) (59)
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. (2002) (59)
Differential specificity for binding of retinoblastoma binding protein 2 to RB, p107, and TATA-binding protein (1994) (57)
Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. (1994) (56)
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (2020) (55)
A pilot test of a combined tobacco dependence treatment and lung cancer screening program. (2012) (54)
Thymomas and thymic carcinomas (2013) (54)
Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and Leukemia Group B 30601): A Brief Report (2012) (53)
CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2014) (51)
Relationship between Overall Survival and Response or Progression‐Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD‐1/PD‐L1 Antibodies (2016) (51)
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non–small cell lung cancer patients with KRAS‐activated tumors (2016) (51)
Lung cancer screening. (2003) (50)
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. (2013) (50)
The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non–Small Cell Lung Cancer (2018) (50)
Bone morphogenetic protein 3B silencing in non-small-cell lung cancer (2004) (50)
Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer (2007) (49)
The Self-regulation Model of Illness Applied to Smoking Behavior in Lung Cancer (2009) (47)
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer (2017) (47)
Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. (2013) (47)
Liquid biopsy for lung cancers: an update on recent developments. (2019) (47)
Crizotinib in Patients With MET-Amplified NSCLC. (2021) (47)
Clinical significance of the FV:Q506 mutation in unselected oncology patients. (1996) (46)
Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors (2013) (44)
Agents to treat BRAF-mutant lung cancer (2019) (44)
Comparative effectiveness of stereotactic radiosurgery versus whole‐brain radiation therapy for patients with brain metastases from breast or non–small cell lung cancer (2016) (43)
A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602) (2010) (42)
Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. (2015) (41)
Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. (1999) (41)
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. (2006) (41)
A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 (2007) (41)
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. (2003) (40)
CDKN2 in HPV‐positive and HPV‐negative cervical‐carcinoma cell lines (1995) (40)
Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. (2018) (39)
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD‐L1 and PD‐1 in Thymoma and Thymic Carcinoma (2018) (39)
RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer (1998) (39)
Incorporation of photodynamic therapy as an induction modality in non‐small cell lung cancer (2006) (36)
An epigenetic mechanism for capecitabine resistance in mesothelioma. (2006) (35)
MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study (2017) (35)
P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. (2003) (34)
Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. (2012) (33)
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. (2004) (33)
Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice (2002) (32)
High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. (2013) (32)
Stable binding to E 2 F is not required for the retinoblastoma protein to activate transcription , promote differentiation , and suppress tumor cell growth (1997) (32)
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. (2008) (31)
OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer (2018) (31)
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors (2013) (30)
Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer (2014) (29)
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. (2015) (29)
Inhibition of cyclin D-CDK 4 / CDK 6 activity is associated with an E 2 F-mediated induction of cyclin kinase inhibitor activity ( human papillomaviruses / cervical cancer / E 7 oncoprotein / retinoblastoma protein ) (29)
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications (2019) (28)
MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells (2010) (28)
Functional analysis at the Cys706 residue of the retinoblastoma protein. (1992) (28)
The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods. (2010) (28)
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer (2016) (28)
A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer (2014) (26)
Genetic etiology of lung cancer. (1992) (25)
First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. (2012) (25)
Altered p16INK4 and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer (2012) (25)
Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer (2005) (25)
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation (2014) (24)
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. (2013) (24)
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. (2004) (24)
Advances in epigenetic therapeutics with focus on solid tumors (2021) (23)
Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses (2014) (22)
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. (2015) (22)
A psychometric analysis of quality of life tools in lung cancer patients who smoke. (2009) (22)
First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1. (2021) (22)
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer (2016) (21)
RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. (1993) (21)
Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice (2008) (19)
Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. (2010) (19)
Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. (2016) (19)
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma (2010) (18)
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer (2010) (18)
A 'core ATPase', Hsp70-like structure is conserved in human, rat, and C. elegans STCH proteins. (1997) (18)
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer. (2012) (17)
Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database (2018) (17)
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis. (2017) (17)
Localization of STCH to human chromosome 21q11.1. (1995) (16)
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. (2021) (15)
Non – Small Cell Lung Cancer, Version 3.2022 (2022) (15)
Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm. (2016) (15)
Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response (2019) (14)
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer (2014) (14)
Impact of immune-related adverse events (irAE) on overall survival (OS) in patients treated with immunotherapy for non-small cell lung cancer (NSCLC). (2017) (14)
Small cell lung cancer in never smokers: report of two cases. (2010) (14)
Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy. (2017) (14)
Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC) (2000) (13)
Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer (2011) (12)
Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice (2009) (12)
41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer (2014) (12)
Randomized Phase II Study of Palifermin for Reducing Dysphagia in Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Unresectable Non-small Cell Lung Cancer (2012) (12)
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. (2021) (11)
Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines. (2000) (11)
Alternative splicing of the RBP1 gene clusters in an internal exon that encodes potential phosphorylation sites. (1993) (11)
Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors (2005) (11)
Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227 (2018) (10)
Overexpression of Rad51C splice variants in colorectal tumors (2014) (10)
Phase I study of 5-aza-2’-deoxycytidine in combination with valproic acid in patients with NSCLC (2008) (10)
Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. (1993) (10)
Rad51C-ATXN7 fusion gene expression in colorectal tumors (2016) (10)
CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis (2020) (10)
Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations (2015) (10)
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. (2012) (10)
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer (2017) (10)
Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients (2006) (9)
Phase I/II Dose-Finding Study of Crizotinib (CRIZ) in Combination with Erlotinib (E) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (9)
Clinical and Metabolic Parameters in Non-Small Cell Lung Carcinoma and Colorectal Cancer Patients with and without KRAS Mutations (2014) (9)
A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC (2020) (9)
Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer (2007) (9)
A pilot trial of G 3139 , a bcl-2 antisense oligonucleotide , and paclitaxel in patients with chemorefractory small-cell lung cancer (2002) (9)
Increased NQO1 but Not c-MET and Survivin Expression in Non-Small Cell Lung Carcinoma with KRAS Mutations (2014) (9)
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies (2009) (9)
Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (8)
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM). (2010) (8)
Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia (2005) (8)
A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors (2005) (8)
CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). (2012) (8)
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer (2020) (8)
Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer. (2020) (8)
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. (2018) (8)
Nontoxic Suramin as a Chemosensitizer in Patients: Dosing Nomogram Development (2006) (8)
The N-Terminal Domain of c-Myc Associates with a-Tubulin and Microtubules In Vivo and In Vitro (1995) (8)
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy (2021) (7)
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. (2013) (7)
Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy. (2019) (7)
Abstract 5500: Inhibition of poly(ADP-ribose) polymerase in lung cancer cells with defective Fanconi anemia (FA) pathway (2011) (7)
RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model. (2002) (7)
Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. (2019) (7)
Immunotherapy in inoperable stage III non-small cell lung cancer: a review (2019) (7)
Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC (2018) (7)
Malignant pleural mesothelioma. (2015) (6)
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events (2021) (6)
O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response (2019) (6)
NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. (2022) (6)
Thymic malignancies. (2010) (6)
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2015) (6)
Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy. (2021) (6)
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer (2017) (6)
Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer (2011) (6)
Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. (2009) (6)
Bone morphogenetic protein 3 B silencing in non-small-cell lung cancer (2004) (6)
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival (2021) (5)
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors (2012) (5)
Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. (2010) (5)
A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). (2013) (5)
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials (2009) (5)
P-229 Phase II evaluation of low dose suramin as a modulator of paclitaxel/carboplatin (P/C) in non-small cell lung cancer (NSCLC) patients (2003) (5)
Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. (2016) (5)
MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma (2017) (5)
Modulation of chemotherapy resistance with low dose suramin in refractory non-small cell lung cancer (NSCLC) patients: A phase I study of sequential non-cross resistant chemotherapy (2005) (4)
Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer. (2011) (4)
Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations. (2020) (4)
Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC (2022) (4)
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers (2020) (4)
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. (2020) (4)
P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC (2021) (4)
Phase 2 Trial of Nab-Paclitaxel Plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding From VEGF Directed Therapies (2014) (4)
Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210) (2020) (4)
Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy † (2015) (4)
Mechanisms of DNA Demethylating Drugs Against Cancer Progression (2005) (3)
Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features (2017) (3)
Phase II study of low dose suramin as a sensitizer of paclitaxel/carboplatin (P/C) in non small cell lung cancer (NSCLC). (2004) (3)
Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy. (2019) (3)
Immune related adverse events across cancer types: Incidence, risk factors and survival. (2018) (3)
Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells (2008) (3)
A Phase I / II Study of LY 900003 , an Antisense Inhibitor of Protein Kinase C-, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non – Small Cell Lung Cancer (2004) (3)
Abstract LB-225: Phase 2 Trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies (2012) (3)
67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 (2020) (3)
Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. (2020) (3)
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy. (2020) (3)
P40.15 Proton Pump Inhibitors, Prior Therapy and Survival in Patients Treated With Immune Checkpoint Inhibitors for Advanced NSCLC (2021) (3)
Mutational Profiling of Second Primary Lung Cancers in Patients Who Have Received Radiation for the Treatment of Hodgkin's Disease (2015) (3)
OA 18.02 The Landscape of Alteration of DNA Integrity-Related Genes and Their Association with Tumor Mutation Burden in Non-Small Cell Lung Cancer (2017) (3)
Photodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series. (2012) (3)
Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. (2011) (2)
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival (2022) (2)
Type of TP53 mutation influences oncogenic potential and spectrum of associated K‐ras mutations in lung‐specific transgenic mice (2019) (2)
The role of methylation leading to capecitabine resistant malignant mesothelioma. (2006) (2)
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (2020) (2)
5-Aza-2 (cid:1) -deoxycytidine Activates the p53/p21 Waf1/Cip1 Pathway to Inhibit Cell Proliferation* (2004) (2)
A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC). (2021) (2)
Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis. (2014) (2)
Abstract A99: Phase I trial of veliparib or mitomycin C + veliparib in pts with Fanconi anemia pathway (FA) repair defects. (2011) (2)
Results of a phase I study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer (2005) (2)
Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. (2020) (2)
Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors? (2018) (2)
A single center review of the experience with mitomycin C (MMC) and the risk of thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) (2007) (2)
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). (2021) (2)
Erratum: Smoking status and survival in the national comprehensive cancer network nonsmall cell lung cancer cohort (Cancer (doi: 10.1002/cncr.27824)) (2013) (1)
6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up (2022) (1)
An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia. (2004) (1)
PS01.09 Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598 (2021) (1)
P21.02 Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation (2021) (1)
Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National Cancer Database (2018) (1)
A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC). (2012) (1)
Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (2015) (1)
Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. (2010) (1)
Molecular Profiling by Next-Generation Sequencing in Nonsmall Cell Lung Cancer (2013) (1)
540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (2020) (1)
Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. (2010) (1)
Neutrophil to lymphocyte ratio, PD-L1 expression, and survival in patients with advanced non-small cell lung cancer receiving first-line immune checkpoint inhibitor therapy. (2020) (1)
Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia. (2005) (1)
Initiation of targeted therapy based on ctDNA only in metastatic NSCLC. (2019) (1)
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. (2011) (1)
Increased Posttreatment Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Marker for Worse Overall Survival in Patients Receiving Concurrent Chemoradiation for Lung Cancer (2016) (1)
Everolimus in thymic epithelial tumors: practical considerations (2018) (1)
Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis. (2011) (1)
A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166. (2020) (1)
Abstract 559: Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway (2015) (1)
Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) with lenalidomide in advanced solid tumors: A phase 1 trial. (2014) (1)
Is immunotherapy toxicity associated with improved overall survival among older adults with advanced cancer? (2019) (1)
P1.01-71 Bone Metastases and Skeletal-Related Events in Patients with Metastatic NSCLC Treated with ICIs: A Multi-Institutional Study (2019) (1)
Abstract 748: Genomic characterization of recurrent small cell lung cancer through research autopsy reveals clonal diversity and candidate driver of chemoresistance (2019) (1)
603 Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors (2012) (1)
Immune pneumonitis-related treatment discontinuations and outcomes in metastatic non-small cell lung cancer treated with nivolumab: A pooled analysis from a multi-institutional international collaboration. (2019) (1)
Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies. (2010) (1)
P48.19 Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center (2021) (1)
NCCN Non – Small Cell Lung Cancer , Version 1 . 2015 Clinical Practice Guidelines in Oncology (2014) (1)
The effectiveness of darbepoetin alfa administered at 300 mcg every 3 weeks on clinical outcomes in elderly patients with chemotherapy-induced anemia. (2006) (1)
P2-230: A Phase I Study of Nontoxic Suramin As A Chemosensitizer In Pretreated/Refractory Non-Small Cell Lung Cancer (NSCLC) Patients (2007) (1)
Cost Consequence Analysis Of Different Gene Mutation Testing Modalities For Braf V600E Mutation In Advanced Non-Small Cell Lung Cancer Using A Decision Analytic Model (2017) (1)
Retrospective analysis of the impact of age on overall survival in patients with non-small cell lung cancer. (2012) (1)
557 PRMT5, a Novel Epigenetic Target in Lung Cancers (2012) (1)
Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report (2023) (1)
615 Preliminary results of a phase I/II study of inhaled doxorubicin combined with docetaxel and cisplatin for advanced non-small cell lung cancer (2004) (0)
Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy” (2021) (0)
Computed tomography (CT) imaging features in early-stage lung adenocarcinoma differentiating exon 19 and exon 21 epidermal growth factor receptor (EGFR) mutated tumors. (2014) (0)
Establishment and characterization of a line of transgenic mice harboring a lung specific human type II p53(175H) mutation (2005) (0)
End of life resource utilization among patients receiving immunotherapy for advanced cancer. (2018) (0)
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy. (2023) (0)
Bone modifying agents and skeletal related events in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. (2021) (0)
PRMT 5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT 5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy Topic : Targets for Treatment Prediction (2016) (0)
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicity in Patients Receiving Concurrent Chemoradiation for Lung Cancer (2016) (0)
Rad51C-ATXN7 fusion gene expression in colorectal tumors (2016) (0)
Non-small cell lung cancer. (2008) (0)
Research Highlights. (2012) (0)
A single institution experience of lung cancer treatment in octogenarians (2007) (0)
Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma. (2017) (0)
Platelets impact the responsiveness of immune checkpoint blockade therapy in solid tumors. (2020) (0)
MR-Predictive Assay in Preoperative Lung Cancer Therapy (2012) (0)
Abstract #5460: Erlotinib in African Americans with lung cancer: a prospective, clinical, molecular, pharmacokinetic and pharmacogenetic characterization (2009) (0)
Malignant Pleural MesotheliomaPractice Guidelines in Oncology (2012) (0)
Correlation of epidermal growth factor receptor (EGFR) mutation profile with computed tomography (CT) imaging features in lung adenocarcinomas. (2013) (0)
P3.02c-056 Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (0)
O-309 Photodynamic therapy (PDT) can be incorporated into the multimodality treatment of loco-regionally advanced non-small cell lung cancer (NSCLC) with obstructive lesions (2003) (0)
Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors (2019) (0)
Abstract 4221: Mutations in Rad51C in colon tumors. (2013) (0)
Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. (2023) (0)
EP08.01-098 Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation (2022) (0)
The experience of first-year hematology and oncology fellows after implementing a wellness chief fellow at an academic cancer center. (2020) (0)
Tumor mutation status of Hodgkin lymphoma survivors with secondary lung adenocarcinoma. (2013) (0)
EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial (2022) (0)
A cell cycle-related RNA expression signature of neoantigen burden in lung adenocarcinoma. (2018) (0)
Early changes in lymphocyte/monocyte ratio on-treatment as a prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitors (2021) (0)
A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors. (2010) (0)
Immune checkpoint inhibitor induced hepatitis: Risk factors, outcomes, and impact on survival. (2021) (0)
EML4-ALK in NSCLC: The OSU Experience. (2011) (0)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration (2020) (0)
1249 Treatment interruptions for immune related adverse events and overall survival in patients with non-small cell lung cancer (NSCLC) treated with first line immune checkpoint inhibitors (ICI) (2022) (0)
Retrospective analysis of pulmonary neuroendocrine/carcinoid tumors at Ohio State University (2007) (0)
P3.17-20 Impact of Significant Primary Tumor Size Reduction on Radiation Dose to Normal Structures in Patients Receiving Definitive Chemoradiotherapy (2018) (0)
244 Repeated Stereotactic Radiosurgery for Recurrent Brain Metastases is Safe and Effective (2009) (0)
Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. (2023) (0)
EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping (2022) (0)
78P Association between obesity, sex, and overall survival in patients with metastatic cancers treated with first- or second-line immune checkpoint inhibitors (2022) (0)
P09.13 Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab (2021) (0)
Abstract 3866: Potential oncogenic function of Rad51C splice variant in colorectal tumors (2015) (0)
Abstract A76: Enhancement of cetuximab-induced antibody-dependent cellular cytotoxicity with lenalidomide in advanced solid tumors: A Phase I trial. (2013) (0)
P-692 Photodynamic therapy (PDT) for primary tracheal carcinoma (2003) (0)
Abstract 4438: Promoter hypermethylation status of Fanconi Anemia (FA) pathway genes FANCF, FANCL and FANCS in non-small cell lung cancer (NSCLC) (2016) (0)
EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy (2022) (0)
P-306 Retrospective analysis of octogenarians with lung cancer (2005) (0)
Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts) (2008) (0)
P-533 Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (2003) (0)
Immune checkpoint inhibitor-related thrombocytopenia: Incidence, risk factors, and effect on overall survival. (2021) (0)
MA 06.08 Lung Cancer Patients with Germline Mutation: A Retrospective Study (2017) (0)
PV-0040: Patterns of care for the elderly with non-surgically treated stage III non-small cell lung cancer (2018) (0)
NSCLC Treated at NCCN Institutions With NCCN Guidelines for Patients Diagnosed With Metastatic First-Line Systemic Therapy Practice Patterns and Concordance (2012) (0)
Abstract 4682: Compensatory activation of alternative DNA repair pathways following exposure to the PARP Inhibitor ABT-888in vitroand in patients with solid malignancies (2012) (0)
Abstract 4246: Promoter hypermethylation and gene expression of FANCF in non-small cell lung cancer (NSCLC). (2013) (0)
P1.04-15 Smoking Status Is Not a Replacement Biomarker for Tumor Mutation Burden in Non-Small Lung Cancer (2019) (0)
P-128 Establishment and characterization of a line of transgenic miceharboring a lung specific human type II p53(175H) mutation; a potential model of human disease (2005) (0)
P2.01-092 PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy: Topic: Targets for Treatment Prediction (2017) (0)
MicroRNA 133B Sensitizes Non Small Cell Lung Cancer to Chemotherapeutic Agents by Targeting BCLw. (2009) (0)
P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor (2017) (0)
Abstract 4740: Establishment of P53 mutant type specific spontaneous lung tumor in transgenic mice for treatment (2012) (0)
CGE23-070: Baseline Neutrophil to Lymphocyte Ratio and Its Change Over Time Predict Overall Survival in Metastatic Non–Small Cell Lung Cancer Patients Who Received First Line Pembrolizumab Therapy (2023) (0)
O-142 Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin™) (2003) (0)
Changes in lymphocyte/monocyte ratio, prognostic marker to predict overall survival in patients with advanced cancer treated with immune checkpoint inhibitor. (2020) (0)
Abstract 4365: Sensitivity of small cell lung cancer cells with defective Fanconi Anemia (FA) pathway to BCL2 inhibitors.. (2013) (0)
Valproic acts as an HDAC inhibitor in cells and works synergistically with the DNMT inhibitor, 5-aza-2′-deoxycytidine (2004) (0)
Re-evaluating the neutrophil-to-lymphocyte ratio: Machine learning-based variable selection for predicting survival at twelve months in late-stage cancer patients receiving immunotherapy. (2019) (0)
A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. (2023) (0)
Lung Cancer ScreeningPractice Guidelines in Oncology (2012) (0)
P78.05 Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome (2021) (0)
Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer. (2019) (0)
Cellular Localization of Protein Arginine Methyltransferase-5 Correlates With Grade of Pulmonary Neuroendocrine Tumors (2013) (0)
PP01.25 Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy (2023) (0)
Dynamic-Contrast Enhanced MR and Volume Regression Rate as a Preoperative Predictive Assay in Patients With Non-Small Cell Lung Cancer (2014) (0)
Abstract 3750: Functional analysis of the Fanconi Anemia pathway in primary lung tumors (2010) (0)
A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation. (2023) (0)
Commentary (Kosuri/Otterson): Coming to Grips With Hand-Foot Syndrome (2004) (0)
Mutant type specific lung cancer models for individualized treatment (2006) (0)
Expression of a mutant p53 in lung specific transgenic mice cause age-related demographic shift in lung tumor incidence (2007) (0)
‘A QUESTION OF INTENT: A Great American Battle with a Deadly Industry’ (2002) (0)
Lung Cancer: Conference Highlights from the 2015 ASCO Annual Meeting (2015) (0)
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications (2020) (0)
P75.12 Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy (2021) (0)
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. (2023) (0)
Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598. (2021) (0)
Advances in epigenetic therapeutics with focus on solid tumors (2021) (0)
442 Pre-treatment interstitial abnormalities is a risk factor for immune checkpoint inhibitor pneumonitis in patients with lung cancer (2022) (0)
48 Phase I study of inhaled doxorubicin combined with docetaxeland cisplatin for advanced non-small cell lung cancer (2005) (0)
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer (2017) (0)
Abstract 854: Inhibition of PRMT5 results in radiosensitization in lung cancer cell lines (2014) (0)
Immunohistochemical staining for programmed cell-death ligand 1 (PD-L1) in malignant thymoma and thymic carcinoma. (2017) (0)
Abstract 4442: micoRNA in FA defective tumor (2017) (0)
Abstract CT141: Phase I study of nivolumab (nivo) +nab-paclitaxel (nab-P) + carboplatin (C) in advanced NSCLC: safety and efficacy results (2016) (0)
EP1.12-38 Retrospective Analysis of Immunotherapy Utilization in Advanced Small Cell Carcinoma at an Academic Cancer Center (2019) (0)
Abstract A43: EGFR-targeted therapy in African Americans with advanced non-small cell lung cancer: A prospective clinical, pharmacogenetic, and pharmacokinetic study. (2012) (0)
Inhaled corticosteroid use and risk of pneumonitis in patients treated with immune checkpoint inhibitors. (2020) (0)
Abstract 2407: Investigation of Novel Rad51c-ATXN7 fusion gene in colorectal tumors (2014) (0)
P79.04 A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis. (2021) (0)
585 Phase 1 dose escalation trial of the selective A2B adenosine receptor antagonist PBF-1129 in patients with metastatic non-small cell lung cancer (mNSCLC) (2022) (0)
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as ﬁ rst-line treatment in patients with advanced non-small-cell lung cancer (0)
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer (2023) (0)
First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. (2010) (0)
Human mutant p53 lung cancer cells respond differently to PRIMA-1 induced apoptosis (2007) (0)
Modulation of Radiation Response of Non-small Cell Lung Cancer Cells with Poly (ADP-Ribose) Polymerase Inhibitor: ABT-888 (2008) (0)
OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001 (2017) (0)
Association of LAG-3 expression in circulating T cells and response to combination temozolomide (TMZ) and nivolumab (NIVO) in advanced neuroendocrine neoplasms (NENs): Results from an investigator-initiated phase 2 trial. (2022) (0)
New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases. (2017) (0)
Low dose suramin as a chemosensitizer in patients: pharmacokinetics, identification and validation of a dosing nomogram (2005) (0)
Abstract 5434: Combined BCL-2/XL and mTor inhibition promotes apoptosis in small cell lung cancer (2014) (0)
Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database (2018) (0)
Abstract 4082: Global miRNA expression changes induced by HDAC-42 and 5-azaCdr in lung cancer cells (2012) (0)
OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial. (2022) (0)
A randomized, double-blind, placebo-controlled multicenter phase II study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed (pem) in advanced non-small cell lung cancer (NSCLC) patients (pts) selected by urinary PGE-m suppression. (2012) (0)
Protein Arginine Methyltransferase-5 as a Novel Epigenetic Target in Lung Cancer (2013) (0)
P2.04-020 Expression Patterns and Prognostic Value of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms (2022) (0)
Palifermin Reduces Dysphagia in Patients with Locally-advanced Unresected Non–small-cell Lung Cancer Undergoing Concurrent Chemoradiotherapy (2009) (0)
Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. (2023) (0)
Neutrophil-lymphocyte score: A novel prognostic scoring system that utilized the dynamic change of neutrophil, lymphocyte, and albumin and its comparison to other indices. (2020) (0)
P-211 Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC) (2003) (0)
Comparative Effectiveness of Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC) (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gregory Alan Otterson?

Gregory Alan Otterson is affiliated with the following schools:

Ohio State University
Stanford University

Gregory Alan Otterson's Academic­Influence.com Rankings

Gregory Alan Otterson's Degrees

Why Is Gregory Alan Otterson Influential?

Gregory Alan Otterson's Published Works

Published Works

What Schools Are Affiliated With Gregory Alan Otterson?

Gregory Alan Otterson's AcademicInfluence.com Rankings